Project Grant F31DA062541

Award Date 7/31/25
Completion Date 1/31/28
Dollars Obligated $98K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award, totaling $400,294, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding supports research to investigate the neurobiological mechanisms by which adverse childhood experiences (ACEs) and chronic stress alter the rewarding effects of the synthetic opioid fentanyl. Specifically, the project aims to determine the therapeutic potential of the serotonin 2A receptor (5-HT2AR) in modulating...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,717,200 to the University of Pittsburgh for research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing new treatments for opioid use disorder (OUD). The project aims to take an unbiased transcriptomics approach to...
This $267,310 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the role of parabrachial CGRP neurons in opioid reinforcement and withdrawal. The objective is to assess the functional role of these neurons in opioid-related behaviors and determine the associated gene expression and epigenetic changes. Researchers will use molecular and pharmacological approaches, including an...
This $2,902,673 project grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to establish OPRM1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management. The funded research will characterize antisense oligonucleotides (ASOs) and rabbit monoclonal antibodies (RabMABs) targeting mouse OPRM1 exon 7 variants, and...
This $847,000 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to evaluate the therapeutic potential of the neuropeptide S receptor 1 (NPSR1) for reducing opioid self-administration and relapse in opioid use disorder (OUD). The research team at the University of Tennessee Health Science Center plans to leverage pharmacological tools to agonize and antagonize the NPSR1 receptor and test...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,076,036 to the University of Pittsburgh to conduct research focused on improving treatments for opioid use disorder (OUD). The key objectives are to: Characterize the relationship between electroencephalography (EEG) signatures in the prefrontal cortex and the function of specific inhibitory neuron subtypes in OUD, to identify potential...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to study the neurophysiological effects of acute opioid use on reward, affect, and pain processing in the human brain. The $159,711 award, granted from January 1, 2025 to December 31, 2029, will leverage direct recordings of neuronal signals from patients with implanted brain electrodes to assess changes in neural connectivity during opioid...
This federal Project Grant award of $606,029.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate the neurocircuitry underlying motivated reward-seeking behavior in response to stress. The key goals of the research are to: 1) Determine if a subpopulation of GABAergic neurons in the medial habenulo-interpeduncular (MHB-IPN) axis...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...

IDENTIFYING A ROLE FOR THE MU-OPIOID RECEPTOR IN THE PARAVENTRICULAR NUCLEUS OF THE THALAMUS IN THE DEVELOPMENT OF STRESS RELATED PHENOTYPES - PROJECT SUMMARY/ABSTRACT STRESS AND STRESSFUL ENVIRONMENTS OFTEN LEAD TO MALADAPTIVE BEHAVIORS THAT CAN INCREASE VULNERABILITY TO SUBSTANCE USE DISORDERS. THE PARAVENTRICULAR NUCLEUS OF THE THALAMUS (PVT) HAS BEEN IMPLICATED IN BOTH STRESS AND DRUG REWARD WITH A POPULATION OF MU-OPIOID RECEPTOR-EXPRESSING NEURONS WITHIN THE PVT (PVT- MOR+ NEURONS) POTENTIALLY IMPORTANT FOR THE MALADAPTIVE BEHAVIORS ASSOCIATED WITH STRESS. INDIVIDUALS' RESPONSE TO STRESS VARIES WITH SOME SHOWING RESILIENCE, WHILE OTHERS SHOW SUSCEPTIBILITY AND ARE PRONE TO THE DETRIMENTAL EFFECTS. WHILE THE RELATIONSHIP BETWEEN STRESS AND SUBSTANCE USE DISORDERS IS WELL DOCUMENTED, THERE EXISTS A SIGNIFICANT GAP IN KNOWLEDGE REGARDING THE ROLE OF INDIVIDUAL DIFFERENCES IN STRESS SUSCEPTIBILITY IN MEDIATING OPIOID REWARD. FURTHERMORE, THE NEURAL PATHWAYS AND CELL TYPES MEDIATING THE DEVELOPMENT OF RESILIENCE OR SUSCEPTIBILITY PHENOTYPES IS UNKNOWN. THE OVERALL GOALS OF THIS PROPOSAL ARE TO A) DETERMINE HOW SUSCEPTIBLE AND RESILIENT PHENOTYPES INFLUENCE SUBSEQUENT OPIOID-TAKING AND B) IF A POPULATION OF MU-OPIOID RECEPTOR (MOR) POSITIVE NEURONS IN THE PVT ARE NECESSARY FOR THE DEVELOPMENT OF STRESS PHENOTYPES. OUR HYPOTHESIS IS A SUSCEPTIBILITY PHENOTYPE FOLLOWING SOCIAL DEFEAT STRESS WILL RESULT IN INCREASES IN OPIOID INTAKE. WE FURTHER HYPOTHESIZE THAT ACTIVATION OF PVT-MOR CONTAINING NEURONS IS NECESSARY FOR ESTABLISHING SUSCEPTIBILITY FOLLOWING CHRONIC SOCIAL STRESS. AIM 1 WILL INVESTIGATE HOW CHRONIC STRESS RESPONSE PHENOTYPES INFLUENCE OPIOID SELF-ADMINISTRATION. AIM 2 WILL EXAMINE THE ROLE OF PVT-MOR+ NEURONS IN THE DEVELOPMENT OF STRESS PHENOTYPES USING CHEMOGENOMIC TOOLS TO MANIPULATE PVT-MOR+ NEURONS DURING CHRONIC SOCIAL DEFEAT STRESS. SUCCESSFUL COMPLETION OF THESE AIMS WILL ESTABLISH IF STRESS RESPONSIVE SUBTYPES DIFFERENTIALLY INFLUENCE OPIOID REINFORCEMENT AND WILL CLARIFY THE ROLE OF PVT-MOR+ NEURONS IN BEHAVIORAL RESPONSES TO CHRONIC SOCIAL STRESS. THROUGH THIS FELLOWSHIP, MS. TYNER WILL ACCOMPLISH THE DEFINED TRAINING GOALS, INCLUDING 1) TECHNICAL TRAINING AND MASTERY OF NEURAL CIRCUIT MANIPULATION AND VIRAL IMAGING TECHNIQUES, 2) EXPERTISE IN THE NEUROBIOLOGY OF STRESS, 3) REFINED WRITTEN AND ORAL SCIENTIFIC COMMUNICATION, AND 4) PROFESSIONAL DEVELOPMENT TOWARDS A CAREER IN ACADEMIC RESEARCH. THIS FELLOWSHIP WILL ALSO FACILITATE PROGRESS TOWARDS ACHIEVING HER CURRENT AND FUTURE RESEARCH GOALS TO ENABLE SUCCESS AS AN INDEPENDENT RESEARCHER.

Posted 1/31/25, 12:00 AM